Literature DB >> 20591474

Symptom presentation in invasive ovarian carcinoma by tumor histological type and grade in a multiethnic population: a case analysis.

Galina Lurie1, Lynne R Wilkens, Pamela J Thompson, Rayna K Matsuno, Michael E Carney, Marc T Goodman.   

Abstract

OBJECTIVE: Although the majority of women with ovarian carcinoma report symptoms prior to diagnosis, little is known about comparative symptom presentation by histological type, stage, grade, or ethnicity.
METHODS: We conducted a population-based study including 622 women with invasive ovarian carcinoma diagnosed from 1993 to 2008. Epidemiological and symptom data were collected using an interviewer-administered questionnaire. Symptoms established as significant predictors of ovarian carcinoma were examined in relation to patient and tumor characteristics, using unconditional multivariate logistic regression and general linear models.
RESULTS: Symptom presentation and duration differed significantly among women with ovarian carcinoma by stage, tumor histology, and grade, but not ethnicity. Significant differences were observed by histology in reporting a distended abdomen, abnormal vaginal bleeding, and bowel symptoms. Compared to women diagnosed with serous carcinoma, women with mucinous tumors were 2.6 times more likely to report a distended abdomen; women with endometrioid carcinoma were three times more likely to report abnormal bleeding. Women with serous tumors were significantly more likely to report bowel symptoms than were women diagnosed with other histological types. The majority of women with serous tumors were diagnosed with advanced cancer and had shorter duration of symptoms than women with early stage disease. In contrast, women with mucinous tumors were generally diagnosed at an early stage and had longer duration of symptoms (p=0.009) if diagnosed at an advanced stage.
CONCLUSION: The study provides evidence that the early diagnosis of ovarian cancer is largely determined by tumor histological type.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20591474      PMCID: PMC2949682          DOI: 10.1016/j.ygyno.2010.05.028

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  21 in total

1.  Incidence of ovarian cancer by race and ethnicity in the United States, 1992-1997.

Authors:  Marc T Goodman; Holly L Howe; Ko Hui Tung; Joellyn Hotes; Barry A Miller; Steven S Coughlin; Vivien W Chen
Journal:  Cancer       Date:  2003-05-15       Impact factor: 6.860

2.  Stage at diagnosis of ovarian cancer in the United States, 1992-1997.

Authors:  Marc T Goodman; Catherine N Correa; Ko-Hui Tung; Steven D Roffers; Xiao Cheng Wu; John L Young; Lynne R Wilkens; Michael E Carney; Holly L Howe
Journal:  Cancer       Date:  2003-05-15       Impact factor: 6.860

3.  Focus on epithelial ovarian cancer.

Authors:  Robert F Ozols; Michael A Bookman; Denise C Connolly; Mary B Daly; Andrew K Godwin; Russell J Schilder; Xiangxi Xu; Thomas C Hamilton
Journal:  Cancer Cell       Date:  2004-01       Impact factor: 31.743

4.  Types and duration of symptoms prior to diagnosis of invasive or borderline ovarian tumor.

Authors:  M F Vine; R B Ness; B Calingaert; J M Schildkraut; A Berchuck
Journal:  Gynecol Oncol       Date:  2001-12       Impact factor: 5.482

5.  Ovarian carcinoma diagnosis.

Authors:  B A Goff; L Mandel; H G Muntz; C H Melancon
Journal:  Cancer       Date:  2000-11-15       Impact factor: 6.860

6.  Symptoms and diagnosis of borderline, early and advanced epithelial ovarian cancer.

Authors:  Penelope M Webb; David M Purdie; Sonia Grover; Susan Jordan; Marie-Louise Dick; Adèle C Green
Journal:  Gynecol Oncol       Date:  2004-01       Impact factor: 5.482

7.  Characterization of prediagnostic symptoms among primary epithelial ovarian cancer cases and controls.

Authors:  Marilyn F Vine; Brian Calingaert; Andrew Berchuck; Joellen M Schildkraut
Journal:  Gynecol Oncol       Date:  2003-07       Impact factor: 5.482

Review 8.  Subclassification of ovarian surface epithelial tumors based on correlation of histologic and molecular pathologic data.

Authors:  C Blake Gilks
Journal:  Int J Gynecol Pathol       Date:  2004-07       Impact factor: 2.762

9.  Prediagnostic symptoms of ovarian carcinoma: a case-control study.

Authors:  Galina Lurie; Pamela J Thompson; Katharine E McDuffie; Michael E Carney; Marc T Goodman
Journal:  Gynecol Oncol       Date:  2009-05-22       Impact factor: 5.482

10.  Differences in symptoms between patients with benign and malignant ovarian neoplasms.

Authors:  Cara A Attanucci; Harrison G Ball; Susan L Zweizig; Annette H Chen
Journal:  Am J Obstet Gynecol       Date:  2004-05       Impact factor: 8.661

View more
  13 in total

1.  Diagnostic and referral intervals for Manitoba women with epithelial ovarian cancer - the Manitoba Ovarian Cancer Outcomes (MOCO) study group: a retrospective cross-sectional study.

Authors:  Allison J Love; Pascal Lambert; Donna Turner; Robert Lotocki; Erin Dean; Shaundra Popowich; Alon D Altman; Mark W Nachtigal
Journal:  CMAJ Open       Date:  2017-02-07

Review 2.  Epidemiology of Patients with Ovarian Cancer with and Without a BRCA1/2 Mutation.

Authors:  Elisabete Weiderpass; Jerzy E Tyczynski
Journal:  Mol Diagn Ther       Date:  2015-12       Impact factor: 4.074

3.  Modified Goff Symptom Index: Simple triage tool for ovarian malignancy.

Authors:  Jyothi Shetty; P Priyadarshini; Deeksha Pandey; A P Manjunath
Journal:  Sultan Qaboos Univ Med J       Date:  2015-08-24

4.  Knockdown of MADD and c-FLIP overcomes resistance to TRAIL-induced apoptosis in ovarian cancer cells.

Authors:  Liang-Cheng Li; Shankar Jayaram; Lakshmy Ganesh; Lixia Qian; Jacob Rotmensch; Ajay V Maker; Bellur S Prabhakar
Journal:  Am J Obstet Gynecol       Date:  2011-05-27       Impact factor: 8.661

5.  Cancer diagnostic tools to aid decision-making in primary care: mixed-methods systematic reviews and cost-effectiveness analysis.

Authors:  Antonieta Medina-Lara; Bogdan Grigore; Ruth Lewis; Jaime Peters; Sarah Price; Paolo Landa; Sophie Robinson; Richard Neal; William Hamilton; Anne E Spencer
Journal:  Health Technol Assess       Date:  2020-11       Impact factor: 4.014

6.  Public perception of risk-reducing salpingectomy for preventing ovarian cancer.

Authors:  Jun Hyeok Kang; Se Hyun Nam; Taejong Song; Woo Young Kim; Kyo Won Lee; Kye Hyun Kim
Journal:  Obstet Gynecol Sci       Date:  2015-07-16

7.  A retrospective analysis of clinicopathological and prognostic characteristics of ovarian tumors in the State of Espírito Santo, Brazil.

Authors:  Marcela F Paes; Renata D Daltoé; Klesia P Madeira; Lucas Cd Rezende; Gabriela M Sirtoli; Alice L Herlinger; Leticia S Souza; Luciana B Coitinho; Débora Silva; Murilo F Cerri; Ana Cristina N Chiaradia; Alex A Carvalho; Ian V Silva; Leticia Ba Rangel
Journal:  J Ovarian Res       Date:  2011-08-09       Impact factor: 4.234

Review 8.  Is increased time to diagnosis and treatment in symptomatic cancer associated with poorer outcomes? Systematic review.

Authors:  R D Neal; P Tharmanathan; B France; N U Din; S Cotton; J Fallon-Ferguson; W Hamilton; A Hendry; M Hendry; R Lewis; U Macleod; E D Mitchell; M Pickett; T Rai; K Shaw; N Stuart; M L Tørring; C Wilkinson; B Williams; N Williams; J Emery
Journal:  Br J Cancer       Date:  2015-03-31       Impact factor: 7.640

9.  Hypodontia phenotype in patients with epithelial ovarian cancer.

Authors:  Anita Fekonja; Andrej Cretnik; Danijel Zerdoner; Iztok Takac
Journal:  Radiol Oncol       Date:  2015-03-03       Impact factor: 2.991

Review 10.  The molecular background of mucinous carcinoma beyond MUC2.

Authors:  Niek Hugen; Michiel Simons; Altuna Halilović; Rachel S van der Post; Anna J Bogers; Monica Aj Marijnissen-van Zanten; Johannes Hw de Wilt; Iris D Nagtegaal
Journal:  J Pathol Clin Res       Date:  2014-11-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.